1. Home
  2. SOAR vs XRTX Comparison

SOAR vs XRTX Comparison

Compare SOAR & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Volato Group Inc.

SOAR

Volato Group Inc.

HOLD

Current Price

$0.56

Market Cap

5.3M

Sector

Finance

ML Signal

HOLD

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

N/A

Current Price

$0.54

Market Cap

4.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOAR
XRTX
Founded
2021
2011
Country
United States
Canada
Employees
N/A
N/A
Industry
Blank Checks
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
4.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SOAR
XRTX
Price
$0.56
$0.54
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.1M
32.9K
Earning Date
11-13-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.32
N/A
Revenue
$58,312,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$0.51
52 Week High
$6.48
$1.41

Technical Indicators

Market Signals
Indicator
SOAR
XRTX
Relative Strength Index (RSI) 36.59 38.46
Support Level $0.41 $0.52
Resistance Level $0.73 $0.60
Average True Range (ATR) 0.08 0.02
MACD 0.01 -0.00
Stochastic Oscillator 39.57 17.50

Price Performance

Historical Comparison
SOAR
XRTX

About SOAR Volato Group Inc.

Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Share on Social Networks: